Therapeutic Specialties Archives

Publication

Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm

Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit…

CertaraJuly 26, 2020

Blog

The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development

3 key tips to set your pediatric program up for success with the RACE for…

CertaraJuly 14, 2020

Publication

Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology

Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat…

CertaraJuly 14, 2020

Blog

Local Therapies for the Global COVID-19 Pandemic

Henri Merdjan explains why topical drug formulations (e.g. intranasal and/or oral) could be valuable as…

CertaraMay 29, 2020

Blog

Applying decision analysis to drug development for COVID-19 & future pandemics

This blog discusses how decision analysis approaches can help drug developers to better decisions under…

CertaraApril 30, 2020

On-Demand Webinar

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

This webinar will explain how pricing has evolved for the rare disease drug market and…

CertaraFebruary 19, 2020

Publication

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

CertaraJanuary 17, 2020

Publication

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

CertaraJanuary 17, 2020

On-Demand Webinar

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…

CertaraAugust 10, 2019

Poster

Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV

CertaraJune 24, 2019

Therapeutic Specialties

Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm

The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development

Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology

Local Therapies for the Global COVID-19 Pandemic

Applying decision analysis to drug development for COVID-19 & future pandemics

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV

Newsletter sign up

Quick links

Solutions

Contact